logo image
search icon
Global Ovarian Cancer Market

Ovarian Cancer Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Hormonal Therapy, Targeted Therapy, and Surgery), Region And Segment Forecasts, 2023-2031.

Report ID : 1067 | Published : 2023-06-17 | Pages: 180 | Format: PDF/EXCEL

The Ovarian Cancer Market is expected to grow at a 10.0% CAGR during the forecast period for 2023-2031.

Ovarian Cancer Market

Ovarian cancer rank fifth in cancer deaths among women and accounting for more deaths than any other cancer of the female reproductive system. Previously it believed that cancer begin only in the ovaries, but recent evidence suggests that many ovarian cancer may start in the fallopian tubes. Factors can increase risk of cancer include older age, genetic mutation such as breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2) and oestrogen hormone replacement therapy. Based on cell of origin ovarian cancer can categorised into three type epithelial tumors, stromal tumors and germ cell tumors. Epithelial tumors begins epithelia tissue of ovarian and it comprise 90% of the ovarian cancers whereas stromal tumors begin from the hormone-producing cell of the ovaries and consist of 7% of the ovarian cancers. According to global estimate 225,000 new cases were detected each year and 140,000 people annually die from the ovarian cancer.


Treatment of ovarian cancer depending on its type and stage. Two types of treatment offer for a patient with ovarian cancer patients include local treatment and systematic treatment. Local treatment consists of surgery and radiation therapy whereas systematic treatment include chemotherapy, hormone therapy and targeted therapy. Successful development of new targeted therapy and recent approval of Avastin (Bevacizumab) and PARP inhibitor such as rubraca (rucaparib), lynparza (olaparib) and zijula (niraparib) will drive the market in forecast period. Additionally, new understanding of the heterogeneity and biology of disease lead to active development of next-generation chemotherapies, new targeted agents and immune-oncology drugs anticipated to further drive market growth.


In January, 2016 The UK National Institute for Health and Care Excellence (NICE) approve AstraZeneca drug Lynparza (olaparib) to treat women with platinum-sensitive relapsed BRAC-mutated high grade ovarian cancer. In July 2018, on the basis of phase 3 trial dubbed GOG -0213, Roche get expanded reimbursement for ovarian cancer therapy. The Avastin previously gained coverage to be used with carboplatin and paclitaxel as first-line combination treatment for patients with high relapsed ovarian cancer. It was also reimburse for use with topotecan or paclitaxel or PEGylated liposomal doxorubicin in platinum resistance ovarian cancer patient who have not previously treated with VEGF-based therapy.

Competitive Landscape

Some of The Key Players in The Ovarian Cancer Market:

  • Pfizer Inc
  • Fresenius Kabi USA, LLC
  • Teva Pharmaceuticals USA, Inc
  • Hoffmann-La Roche AG
  • AstraZeneca
  • Tesaro Inc
  • Clovis Oncology, Inc.
  • Other Prominent Players

The Ovarian Cancer Market Report Scope

Report Attribute

Specifications

Growth Rate CAGR

CAGR of 10.0 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Treatment

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Pfizer Inc. Fresenius Kabi USA, LLC, Teva Pharmaceuticals USA, Inc., F. Hoffmann-La Roche AG. AstraZeneca, Tesaro Inc. Clovis Oncology, Inc., and Others

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Ovarian Cancer Market Snapshot

Chapter 4. Global Ovarian Cancer Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis

5.1. By Treatment & Market Share, 2022 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Treatment:

5.2.1. Chemotherapy

5.2.2. Targeted Therapy

5.2.3. Hormonal Therapy

5.2.4. Surgery

Chapter 6. Ovarian Cancer Market Segmentation 2: Regional Estimates & Trend Analysis

6.1. North America

6.1.1. North America Ovarian Cancer Market revenue (US$ Million) estimates and forecasts By Treatment, 2022 - 2030

6.1.2. North America Ovarian Cancer Market revenue (US$ Million) estimates and forecasts by country, 2022 - 2030

6.2. Europe

6.2.1. Europe Ovarian Cancer Market revenue (US$ Million) By Treatment, 2022 - 2030

6.2.2. Europe Ovarian Cancer Market revenue (US$ Million) by country, 2022 - 2030

6.3. Asia Pacific

6.3.1. Asia Pacific Ovarian Cancer Market revenue (US$ Million) By Treatment, 2022 - 2030

6.3.2. Asia Pacific Ovarian Cancer Market revenue (US$ Million) by country, 2022 - 2030

6.4. Latin America

6.4.1. Latin America Ovarian Cancer Market revenue (US$ Million) By Treatment, (US$ Million)

6.4.2. Latin America Ovarian Cancer Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

6.5. Middle East & Africa

6.5.1. Middle East & Africa Ovarian Cancer Market revenue (US$ Million) By Treatment, (US$ Million)

6.5.2. Middle East & Africa Ovarian Cancer Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

Chapter 7. Competitive Landscape

7.1. Major Mergers and Acquisitions/Strategic Alliances

7.2. Company Profiles

7.2.1. Pfizer Inc

7.2.2. Fresenius Kabi USA, LLC

7.2.3. Teva Pharmaceuticals USA, Inc

7.2.4. F. Hoffmann-La Roche AG

7.2.5. AstraZeneca

7.2.6. Tesaro Inc

7.2.7. Clovis Oncology, Inc.

7.2.8. Other Key Players

Global Ovarian Cancer Market Segmentation

Global Ovarian Cancer Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Treatment

  • Chemotherapy
  • Targeted Therapy
  • Hormonal Therapy
  • Surgery

Ovarian Cancer Market

Global Ovarian Cancer Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region

  • Europe
    • K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

What is the Ovarian Cancer Market Growth?

Pfizer Inc. Fresenius Kabi USA, LLC, Teva Pharmaceuticals USA, Inc., F. Hoffmann-La Roche AG. AstraZeneca, Tesaro Inc. Clovis Oncology, Inc., and Othe

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach